Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Claim extract · Listening Library

Hamilton Morris media: iboga fieldwork, chemistry literacy, and addiction narratives

LAST REVIEWED 2026-09-22 · MEDIA / DOCUMENTARY · NOT A CLINICAL TRIAL

High-confidence Listening Library rows featuring Hamilton Morris place iboga in Gabonese ritual and chemistry context. Useful for culture and literacy; efficacy talk stays media-labeled until primary literature is cited.

Chemistry / culture media Not clinical proof Cardiac risk still applies

Listening Library sources (outbound)

Testable claims extracted (media → primary)

  1. Claim (media): Public “addiction cure” narratives differ from Gabonese ritual/cultural settings.
    Primary (ethnography / subculture documentation): Alper KR, Lotsof HS, Kaplan CD. “The ibogaine medical subculture.” J Ethnopharmacol 2008. PMID 18029124, DOI 10.1016/j.jep.2007.08.034. Label: documents a medical subculture — not efficacy proof.
  2. Claim (media / chemistry): Iboga alkaloids carry meaningful cardiac ion-channel risk relevant to clinical caution.
    Primary: Alper K et al. “hERG Blockade by Iboga Alkaloids.” Cardiovasc Toxicol 2016. PMID 25636206, DOI 10.1007/s12012-015-9311-5. Pair with Safety / QTc.
  3. Claim (overclaim): Documentary fieldwork or podcast chemistry literacy proves that ibogaine “cures addiction.”
    Verdict: Overstated — cure-language check + OUD.
  4. Claim (policy myth): Media visibility equals FDA approval.
    Verdict: False — FDA-approval check + Schedule I vs state bills FAQ.

Verdict

Strong culture / chemistry literacy media; not a substitute for controlled trials, denominators, or cardiac-risk desks. Keep Bwiti / stewardship context on culture pages separate from biomedical claims.

Continue reading